Jaimee L Heffner1, Jennifer B McClure2, Kristin E Mull1, Robert M Anthenelli3, Jonathan B Bricker1,4. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2. Group Health Research Institute, Seattle, WA, USA. 3. Department of Psychiatry, University of California, San Diego School of Medicine, San Diego, CA, USA. 4. Department of Psychology, University of Washington, Seattle, WA, USA.
Abstract
OBJECTIVES:People with bipolar disorder are two to three times more likely to smoke and 50% less likely to quit than the general population. New treatments are needed to improve smoking cessation outcomes in this group. The study aim was to develop and pilot test a novel cessation intervention for smokers with bipolar disorder using Acceptance and Commitment Therapy (ACT) combined withnicotine patches. METHODS: The ten-session ACT intervention was initially evaluated as in-person, individual counseling (n = 10), then as telephone-delivered counseling (n = 6). Participants were adult smokers with no more than mild current symptoms of bipolar disorder. RESULTS: For the in-person protocol, end-of-treatment outcomes were: 80% retention, 40% of participants with carbon monoxide (CO)-verified seven-day point prevalence abstinence (PPA), 90% satisfied with treatment, 8.3 of ten sessions attended, and 54% increase in acceptance of cravings to smoke (i.e., ACT's theory-based change process) from baseline. The seven-day PPA at one-month follow-up was 30%. For the telephone protocol, end-of-treatment outcomes were: 67% retention, 33% reporting seven-day PPA, 100% satisfied with treatment, 6.7 of ten treatment calls completed, and 55% increase in acceptance from baseline. At one-month follow-up, seven-day PPA was 17%. The proportion of treatment completers who used at least 80% of the nicotine patches was 62.5% for the in-person protocol and 0% for the telephone protocol. CONCLUSIONS: Both in-person and telephone-delivered ACT were feasible. Despite low adherence to nicotine patches, the intervention showed preliminary evidence of facilitating quitting and impacting ACT's change mechanism. A randomized, controlled trial of this targeted ACT intervention is now needed.
RCT Entities:
OBJECTIVES:People with bipolar disorder are two to three times more likely to smoke and 50% less likely to quit than the general population. New treatments are needed to improve smoking cessation outcomes in this group. The study aim was to develop and pilot test a novel cessation intervention for smokers with bipolar disorder using Acceptance and Commitment Therapy (ACT) combined with nicotine patches. METHODS: The ten-session ACT intervention was initially evaluated as in-person, individual counseling (n = 10), then as telephone-delivered counseling (n = 6). Participants were adult smokers with no more than mild current symptoms of bipolar disorder. RESULTS: For the in-person protocol, end-of-treatment outcomes were: 80% retention, 40% of participants with carbon monoxide (CO)-verified seven-day point prevalence abstinence (PPA), 90% satisfied with treatment, 8.3 of ten sessions attended, and 54% increase in acceptance of cravings to smoke (i.e., ACT's theory-based change process) from baseline. The seven-day PPA at one-month follow-up was 30%. For the telephone protocol, end-of-treatment outcomes were: 67% retention, 33% reporting seven-day PPA, 100% satisfied with treatment, 6.7 of ten treatment calls completed, and 55% increase in acceptance from baseline. At one-month follow-up, seven-day PPA was 17%. The proportion of treatment completers who used at least 80% of the nicotine patches was 62.5% for the in-person protocol and 0% for the telephone protocol. CONCLUSIONS: Both in-person and telephone-delivered ACT were feasible. Despite low adherence to nicotine patches, the intervention showed preliminary evidence of facilitating quitting and impacting ACT's change mechanism. A randomized, controlled trial of this targeted ACT intervention is now needed.
Authors: J B McClure; H Derry; K R Riggs; E W Westbrook; J St John; S M Shortreed; A Bogart; L C An Journal: Contemp Clin Trials Date: 2012-07-04 Impact factor: 2.226
Authors: Mark A Frye; Jon O Ebbert; Courtney A Prince; Timothy W Lineberry; Jennifer R Geske; Christi A Patten Journal: J Clin Psychopharmacol Date: 2013-12 Impact factor: 3.153
Authors: K K Bucholz; R Cadoret; C R Cloninger; S H Dinwiddie; V M Hesselbrock; J I Nurnberger; T Reich; I Schmidt; M A Schuckit Journal: J Stud Alcohol Date: 1994-03
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Jonathan B Bricker; Kristin E Mull; Julie A Kientz; Roger Vilardaga; Laina D Mercer; Katrina J Akioka; Jaimee L Heffner Journal: Drug Alcohol Depend Date: 2014-07-17 Impact factor: 4.492
Authors: Andrea H Weinberger; Jennifer C Vessicchio; Kristi A Sacco; Cerissa L Creeden; K N Roy Chengappa; Tony P George Journal: J Clin Psychopharmacol Date: 2008-10 Impact factor: 3.153
Authors: K N Roy Chengappa; Kenneth A Perkins; Jaspreet S Brar; Patricia J Schlicht; Scott R Turkin; Michelle L Hetrick; Michele D Levine; Tony P George Journal: J Clin Psychiatry Date: 2014-07 Impact factor: 4.384
Authors: Jaimee L Heffner; Noreen L Watson; Jennifer B McClure; Robert M Anthenelli; Sarah Hohl; Jonathan B Bricker Journal: J Dual Diagn Date: 2018-01-19
Authors: Jaimee L Heffner; Kristin E Mull; Noreen L Watson; Jennifer B McClure; Jonathan B Bricker Journal: Drug Alcohol Depend Date: 2018-10-10 Impact factor: 4.492
Authors: Jaimee L Heffner; Megan M Kelly; Jeanette Waxmonsky; Kristin Mattocks; Edit Serfozo; Jonathan B Bricker; Kristin E Mull; Noreen L Watson; Michael Ostacher Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Jaimee L Heffner; A Eden Evins; Cristina Russ; David Lawrence; Catherine R Ayers; Thomas McRae; Lisa St Aubin; Alok Krishen; Robert West; Robert M Anthenelli Journal: J Affect Disord Date: 2019-06-03 Impact factor: 4.839